Ipilimumab biosimilar is under clinical development by CStone Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ipilimumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ipilimumab biosimilar overview
Ipilimumab biosimilar (CS-1002) is under development for the treatment of solid tumors including colorectal cancer, hepatocellular carcinoma, malignant pleural mesothelioma, pancreatic adenocarcinoma, prostate cancer, gastro-intestinal stromal tumor, esophageal cancer, metastatic melanoma, metastatic adenocarcinoma and cholangiocarcinoma. The drug candidate is an immunoglobulin G (IgG) 1 class, fully human monoclonal antibody (mAb). It is administered through the intravenous drip route. It acts by targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4).
CStone Pharmaceuticals overview
CStone Pharmaceuticals is a biopharmaceutical company. It develops and commercializes immuno-oncology and precision medicine to address the unmet medical needs of cancer patients. The company’s pipeline product portfolio includes Ivosidenib (CS3010) for the treatment of acute myeloid leukemia (AML); CS1001 to treat solid tumors; Avapritinib (CS3007) for the treatment of liver diseases; CS1002, CS1003, CS3006, CS3003, CS3002 to treat solid tumors. CStone Pharmaceuticals operates clinical research institutions for developing anti-cancer drugs. The company’s partners include Agios Inc, Blueprint Medicines Corp and WuXi Biologics. CStone Pharmaceuticals is headquartered in Shanghai, China.
For a complete picture of Ipilimumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
